A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

which looked at the drug in Alzheimer’s disease. But Axovant said it will continue to develop nelotanserin to treat hallucinations in patients with Parkinson’s disease dementia, and is ...

Dementia with Lewy bodies ... so the discovery that commonly used drugs may reduce the risk of the disease is a beacon of hope for patients and their carers. The main finding of the observational ...

(“Alpha”) of the improved new drug ZUNVEYL ... in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of ...

The study, carried out by experts from the University of Nottingham and funded by the National Institute for Health Research (NIHR), found that there was nearly a 50% increased risk of dementia among ...